Introduction
According to World Health Organization estimates, more than 2000 million people have been infected with HBV worldwide and about 350 million have persistent infection. HBV may be the cause of up to 80% of all cases of hepatocellular carcinoma worldwide, second only to tobacco among known human carcinogens. Approximately, 1 million people around the world die each year from hepatocellular carcinoma or liver failure. Control of HBV infection is therefore, an important goal for public health in areas of endemicity [1] [2] [3] [4] [5] 
Materials and methods
This is a retrospective, cross sectional type of study which was conducted in AFIP, Dhaka Cantonment. The study was carried out from 29 July, 2013 to 30 October, 2013. Study populations were HBsAg positive patients of both sex and age limit was up to 60 years. A total of 56 HBsAg positive patients were identified from CMH, Dhaka cantonment, Dhaka. Relevant history was taken from the patients. With the written consent of the patients, firstly, HBV-DNA was detected and quantified by rt-PCR in the molecular biology laboratory, AFIP and secondly, serum HBeAg and anti-HBe were detected by ELISA in the Immunology Department, AFIP, Dhaka Cantonment.
Detection and quantitation of HBV-DNA by rt PCR:
The detection was done by the fluorescent labelling of oligonucleotide probes that bind specifically to the PCR amplicone. Detection of the fluorescence intensity during the course of rt-PCR enables verification as well as quantitation of the product. For HBV-DNA the artus HBV RG PCR kit (QIAGEN, Germany) covers a linear range from 1.1 IU/ml to at least 4x10 9 IU/ml.
DNA extraction: DNA was extracted from 200μl of plasma with DNA extraction kit, dissolved in buffer and stored at -20º C till used for PCR.
Real time PCR:
The HBV Rotor Gene PCR kit was ready to use for real time PCR. The HBV RG Master contained all the reagents and enzymes for the specific amplification of a 134 base pair sequence of the HBV genome and for the direct detection of the specific amplicon in fluorescence channel Cycling Green of the Rotor-Gene Q. In addition, the artus HBV RG PCR kit contained a second heterogonous amplification system to identify possible PCR inhibition. This was detected as an internal control in fluorescence Finally the amplification was performed in a 50μl reaction mixture containing 30 μl mixture of HBV RG Master mix (Buffer, dNTP, Primer, Probe and enzymes) and 20μl of eluted sample DNA to each reaction. Correspondingly, 20 μl of 5 quantitation standards were used as positive controls and 20 μl of water as a negative control.
The rt-PCR cycling parameters consisted of denaturation at 95º C for 10 minutes followed by 45 cycles consisting of 95º C for 15 sec, 55º C for 30 sec and 72º C for 15 seconds.
The problem of contamination was avoided by using pre-sterilized filtered micro tips and the reaction was run in a closed system. The amplification detection was carried out in a Rotor Gene Q Sequence detector. The rt-PCR uses target amplification techniques in which quantitation takes place during the exponential phase of amplification reaction.
Results
A total of 56 HBsAg positive patients were selected for the present study. Among them, HBV-DNA was detected among 34(60.7%) patients. Twenty two (39.3%) patients were negative for the test (Table-I) . Among 56 HBsAg positive patients, 15 patients were receiving anti-viral therapy. Out of them, 4 patients showed decreased viral load and HBV-DNA could not be detected in 11 patients (comparative study was done by taking the previous record of HBV-DNA load of the same patients from AFIP) ( Table-IV) . On the other hand, among 22 (39.3%) HBV-DNA negative patients, none were HBeAg positive and 10 (45.5%) patients were anti-HBe positive which indicates that the patients may be of silent infection which correlates with the study of MR Md et al 17 .
Twelve (54.5%) patients were negative by both the tests (HBeAg and anti-HBe) which indicates that the patients may be of precore mutant variety or carriers which correlate with the study of Yun-Fan et al 15 .
In this study, among the 56 HBsAg positive patients, HBeAg was positive in 8(14.28%) patients which also coincides with the study by Chopra GS et al which showed that 26% patients were positive for HBeAg among HBsAg positive patients 3 .
The present data indicates that the HBeAg and anti-HBe status do not necessarily reflect the HBV-DNA level in the serum. So, the assay may be useful for patients who are HBeAg negative but carry 22 . Asymptomatic HBsAg positive carriers should not be considered as having inactive disease. They should be followed up every 3 to 6 months to know the activity of the disease and development of complications. Majority of these carriers suffer from chronic hepatitis rather than acute hepatitis probably contracting the disease in perinatal period or early childhood 17 .
HBV-DNA persists throughout the natural history of chronic hepatitis B, even in patients with serologic evidence of viral clearance. Ttreatment does not generally allow complete eradication of HBV from the organism. Continuous long-term therapy is required to maintain effective viral suppression and symptom control 23 . In the present study, among the 15 treatment receiving patients, viral load was decreased in 4 (26.6%) patients and viral load could not be detected in 11(73.4%) patients after effective treatment which correspond with the study by Chopra GS et.al (63%) 3 . Antivirals used for these patients were nucleoside analogs such as Entecavir, Lamivudine, Telbivudine. These antivirals were used for various durations (ranging from 3 months to 10 years) according to individual patient's requirement.
Conclusion
Prevalence rates of HBV vary across the world with the highest rates being observed in eastern Asia. Thus, the high sensitivity, specificity, accuracy, wide linearity, good reproducibility combined with a small sample volume equirement make this quantitative HBV rt-PCR assay in routine diagnostic laboratories well suited for application to large clinical and epidemiological studies.
